PainResearch Phase

Dermorphin

Intracerebroventricular, Subcutaneous injection

Overview

Dermorphin is a heptapeptide opioid agonist originally isolated from the skin of South American Phyllomedusa frogs. It exhibits high selectivity and affinity for the mu-opioid receptor, with potency approximately 30 to 40 times greater than morphine in animal models.

Mechanism of Action

The unique D-alanine residue at position 2 confers resistance to peptidase degradation and contributes to its prolonged analgesic activity. Its potent receptor binding has made it a valuable research tool for studying opioid receptor pharmacology..

Research Summary & Key Findings

Preclinical studies in rodents have demonstrated potent antinociceptive effects following intracerebroventricular and systemic administration. Dermorphin has been used extensively in laboratory settings to map mu-opioid receptor distribution and function. No human clinical trials have been conducted, and its use remains confined to experimental neuropharmacology research.

Clinical Status

Research Phase

Dermorphin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

IntracerebroventricularSubcutaneous injection

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Dermorphin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Dermorphin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.